Arvinas Stock Price, News & Analysis

Arvinas, Inc. (NASDAQ: ARVN) is a clinical-stage biotechnology company headquartered in New Haven, Connecticut. The company focuses on improving the lives of patients with debilitating and life‑threatening diseases by developing therapies based on targeted protein degradation. Arvinas is advancing a pipeline of investigational drugs built on its proprietary PROTAC (PROteolysis TArgeting Chimera) protein degrader platform, which is designed to harness the body’s natural protein disposal system to selectively degrade and remove disease‑causing proteins.

Business focus and therapeutic areas

Arvinas describes itself as a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation. According to company disclosures and press releases, it is progressing multiple investigational PROTAC degraders through clinical development in oncology and neurology, and in other serious conditions where disease‑causing proteins play a central role.

The company’s development programs include:

• Vepdegestrant (ARV‑471), an investigational, orally bioavailable PROTAC estrogen receptor (ER) degrader targeting the estrogen receptor for adults with locally advanced or metastatic ER‑positive/HER2‑negative breast cancer. It is being developed as a potential monotherapy for ESR1‑mutated ER+/HER2‑ advanced or metastatic breast cancer previously treated with endocrine‑based therapy, in collaboration with Pfizer Inc.
• ARV‑393, an investigational PROTAC BCL6 degrader targeting B‑cell lymphoma 6 protein (BCL6) for patients with relapsed/refractory non‑Hodgkin lymphoma, including diffuse large B‑cell lymphoma. ARV‑393 is being evaluated in a Phase 1 clinical trial.
• ARV‑806, a novel, investigational PROTAC degrader designed to selectively target and degrade mutant KRAS G12D, the most common mutation of the KRAS protein. ARV‑806 is in a Phase 1 clinical trial in patients with advanced solid tumors harboring KRAS G12D mutations, such as pancreatic, colorectal and lung cancers.
• ARV‑102, an oral PROTAC leucine‑rich repeat kinase 2 (LRRK2) degrader being developed for neurodegenerative disorders, including Parkinson’s disease. Arvinas has reported data from Phase 1 clinical trials in healthy volunteers and patients with Parkinson’s disease and is intensifying development based on these findings.

PROTAC protein degrader platform

Arvinas’ core technology is its PROTAC protein degrader platform. The company states that PROTAC degraders are designed to harness the ubiquitin‑proteasome system, the cell’s natural protein disposal machinery, to selectively and efficiently degrade disease‑causing proteins. Rather than inhibiting a protein’s function, PROTAC molecules are intended to induce the target protein’s degradation, which may help address proteins that have historically been considered “undruggable.”

In its public communications, Arvinas highlights that PROTAC‑mediated degradation has potential applications across oncology, neurodegeneration and other serious diseases where pathogenic proteins drive disease biology. Programs such as ARV‑393 for BCL6‑driven lymphomas, ARV‑806 for KRAS G12D‑mutated cancers, and ARV‑102 for LRRK2‑associated neurodegenerative disease exemplify how the platform is being applied to distinct molecular targets.

Key pipeline programs

Across its news releases and SEC filings, Arvinas describes several key clinical and preclinical programs:

• Vepdegestrant (ARV‑471): An investigational PROTAC ER degrader for ER+/HER2‑ breast cancer, including ESR1‑mutated advanced or metastatic disease previously treated with endocrine‑based therapy. A global Phase 3 trial (VERITAC‑2) has evaluated vepdegestrant as a monotherapy versus fulvestrant, and the U.S. Food and Drug Administration has accepted a New Drug Application for this indication with an assigned Prescription Drug User Fee Act (PDUFA) action date. Vepdegestrant has received Fast Track designation from the FDA. Arvinas and Pfizer share worldwide development costs, commercialization expenses and profits, and have jointly agreed to seek a third‑party partner for commercialization and potential further development.
• ARV‑393: An investigational, orally bioavailable PROTAC designed to degrade BCL6, a transcriptional repressor and major driver of B‑cell lymphomas. Arvinas reports that ARV‑393 is being studied in a Phase 1 clinical trial in patients with relapsed/refractory non‑Hodgkin lymphoma, with plans to evaluate it in combination with glofitamab, a CD20×CD3 bispecific antibody, as a chemotherapy‑free approach in diffuse large B‑cell lymphoma.
• ARV‑806: A PROTAC KRAS G12D degrader designed to target both the ON and OFF forms of KRAS G12D. Company disclosures note that KRAS is one of the most frequently mutated human oncogenes and that the G12D mutation is common in solid tumors such as pancreatic, colorectal and lung cancer. ARV‑806 is being evaluated in a Phase 1 trial in patients with advanced solid tumors harboring KRAS G12D mutations.
• ARV‑102: An oral PROTAC LRRK2 degrader for neurodegenerative disorders. Arvinas has presented Phase 1 data in healthy volunteers and in patients with Parkinson’s disease, describing dose‑dependent target engagement, brain penetration and effects on biomarkers associated with LRRK2‑driven pathways.
• Additional early programs: Company communications also reference investigational candidates such as ARV‑027, an oral PROTAC polyQ‑AR degrader being evaluated preclinically for spinal bulbar muscular atrophy, and ARV‑6723, an oral PROTAC HPK1 degrader in preclinical development for advanced solid tumors.

Collaborations and corporate actions

Arvinas reports a global collaboration with Pfizer for the co‑development and co‑commercialization of vepdegestrant, under which the companies share worldwide development costs, commercialization expenses and profits. In later disclosures, Arvinas and Pfizer state that they have jointly agreed to out‑license the commercialization rights to vepdegestrant to a third party and are seeking a partner to maximize its commercial potential, if approved, and potentially develop it in additional settings.

In an 8‑K filing, Arvinas also describes organizational and capital allocation actions, including a workforce reduction primarily related to vepdegestrant commercialization roles and a share repurchase program authorized by its Board of Directors. These steps are presented as part of efforts to refocus on early development programs and manage operating expenses while advancing the pipeline.

Regulatory and clinical disclosure

Through its SEC filings, Arvinas provides updates on clinical trial data, regulatory milestones and corporate developments. For example, the company has filed current reports on Form 8‑K to describe acceptance of the New Drug Application for vepdegestrant by the FDA, presentation of Phase 1 data for ARV‑102 in Parkinson’s disease, and preclinical data for ARV‑806 and ARV‑393 at major scientific meetings.

These filings also include forward‑looking statements regarding anticipated clinical milestones, regulatory interactions and development plans, which are subject to risks and uncertainties as described in the company’s periodic reports.

Headquarters and listing

Arvinas states that it is headquartered in New Haven, Connecticut, and its common stock trades on the Nasdaq Stock Market under the ticker symbol ARVN. The company identifies itself as a clinical‑stage biotechnology issuer and files reports with the U.S. Securities and Exchange Commission, including Forms 10‑K, 10‑Q and 8‑K.

Position within biotechnology and protein degradation

According to its public descriptions, Arvinas is “pioneering the development of protein degradation therapies” through its PROTAC platform. Its programs span oncology indications such as ER+/HER2‑ breast cancer, non‑Hodgkin lymphoma and KRAS G12D‑mutated solid tumors, as well as neurodegenerative disorders linked to LRRK2. By focusing on targeted protein degradation, the company aims to address diseases driven by proteins that may be difficult to modulate with traditional small‑molecule inhibitors.

Investors and researchers analyzing ARVN stock often review the company’s clinical‑stage pipeline, collaborations, regulatory milestones and SEC filings to understand its development progress and risk profile as a biotechnology issuer focused on medicinal and biological products.

ARVN stock: what investors monitor

For those researching ARVN stock, key areas of focus based on Arvinas’ own disclosures include:

• Progress and regulatory status of vepdegestrant in ER+/HER2‑ ESR1‑mutated advanced or metastatic breast cancer.
• Clinical data from early‑stage programs such as ARV‑102, ARV‑393 and ARV‑806.
• Updates on collaborations, including the Pfizer partnership and any third‑party commercialization agreements for vepdegestrant.
• Corporate actions disclosed in SEC filings, such as workforce reductions, cost management measures and share repurchase authorizations.

All of these elements are drawn from Arvinas’ public statements and regulatory filings and form the basis for understanding the company’s business model and development strategy.